147 related articles for article (PubMed ID: 10526537)
41. Chromosomal aberrations in transitional cell carcinoma: its correlation with tumor behavior.
Yu DS; Chen HI; Chang SY
Urol Int; 2002; 69(2):129-35. PubMed ID: 12187044
[TBL] [Abstract][Full Text] [Related]
42. [Analysis of numerical chromosomal aberrations in bladder cancer detected by fluorescence in situ hybridization].
Oka F
Nihon Ika Daigaku Zasshi; 1995 Oct; 62(5):501-10. PubMed ID: 7499466
[TBL] [Abstract][Full Text] [Related]
43. Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization.
Yokogi H; Wada Y; Moriyama-Gonda N; Igawa M; Ishibe T
Br J Urol; 1996 Nov; 78(5):699-703. PubMed ID: 8976763
[TBL] [Abstract][Full Text] [Related]
44. Comparison of comparative genomic hybridization, fluorescence in situ hybridization and flow cytometry in urinary bladder cancer.
Mahdy E; Yoshihiro S; Zech L; Wester K; Pan Y; Busch C; Döhner H; Kallioniemi O; Bergerheim U; Malmström PU
Anticancer Res; 1999; 19(1A):7-12. PubMed ID: 10226518
[TBL] [Abstract][Full Text] [Related]
45. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer.
Inoue T; Nasu Y; Tsushima T; Miyaji Y; Murakami T; Kumon H
Urol Res; 2000 Jan; 28(1):57-61. PubMed ID: 10732697
[TBL] [Abstract][Full Text] [Related]
46. Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma.
Panani AD; Roussos C
Anticancer Res; 2006; 26(1A):319-23. PubMed ID: 16475713
[TBL] [Abstract][Full Text] [Related]
47. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.
Qian J; Bostwick DG; Takahashi S; Borell TJ; Herath JF; Lieber MM; Jenkins RB
Cancer Res; 1995 Nov; 55(22):5408-14. PubMed ID: 7585610
[TBL] [Abstract][Full Text] [Related]
48. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
[TBL] [Abstract][Full Text] [Related]
49. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K
Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431
[TBL] [Abstract][Full Text] [Related]
50. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
51. Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex fluorescence in situ hybridization.
Stamouli MI; Panani AD; Ferti AD; Petraki C; Oliver RT; Raptis SA; Young BD
Cancer Genet Cytogenet; 2004 Mar; 149(2):107-13. PubMed ID: 15036885
[TBL] [Abstract][Full Text] [Related]
52. Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis.
Poddighe PJ; Bringuier PP; Vallinga M; Schalken JA; Ramaekers FC; Hopman AH
J Pathol; 1996 Jun; 179(2):169-76. PubMed ID: 8758209
[TBL] [Abstract][Full Text] [Related]
53. Detection of C-erb B2 gene amplification in bilharzial associated bladder cancer using fluorescence in situ hybridization.
Aly MS; Khaled HM
Urol Oncol; 2004; 22(6):448-52. PubMed ID: 15610859
[TBL] [Abstract][Full Text] [Related]
54. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations.
Zhang FF; Arber DA; Wilson TG; Kawachi MH; Slovak ML
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2317-28. PubMed ID: 9815630
[TBL] [Abstract][Full Text] [Related]
55. Molecular cytogenetic characterization and diagnostics of bladder cancer.
Houskova L; Zemanova Z; Babjuk M; Melichercikova J; Pesl M; Michalova K
Neoplasma; 2007; 54(6):511-6. PubMed ID: 17949235
[TBL] [Abstract][Full Text] [Related]
56. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer.
Sauter G; Moch H; Carroll P; Kerschmann R; Mihatsch MJ; Waldman FM
Int J Cancer; 1995 Apr; 64(2):99-103. PubMed ID: 7615360
[TBL] [Abstract][Full Text] [Related]
57. [Detection of chromosomal numerical aberration in glioma by FISH (fluorescence in situ hybridization)].
Kasai H; Imahori T; Kawamoto K
Hum Cell; 1993 Mar; 6(1):62-5. PubMed ID: 8343450
[TBL] [Abstract][Full Text] [Related]
58. DNA flow cytometric analysis and numerical chromosome 9 aberrations detected by interphase cytogenetics in superficial bladder TCC.
Eleuteri P; Grollino MG; Pomponi D; Calugi G; Rocchi M; De Vita R
Eur J Histochem; 1997; 41 Suppl 2():161-2. PubMed ID: 9859830
[No Abstract] [Full Text] [Related]
59. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
60. [Ki-67 fraction, p53 alteration and numerical chromosome aberrations (chromosomes 7 and 17) in formalin fixed bladder tumors].
Moch H; Sauter G; Gudat F; Waldman F; Mihatsch MJ
Verh Dtsch Ges Pathol; 1993; 77():226-30. PubMed ID: 7511286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
